ATEA PHARMACEUTICALS INC (AVIR) Stock Analyst Ratings
NASDAQ:AVIR - US04683R1068 - Common Stock
3.655 USD
+0 (+0.14%)
ChartMill assigns a Buy % Consensus number of 83% to AVIR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.12. This target is 67.44% above the current price.
AVIR was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about AVIR.
In the last month the buy percentage rose by 33 points. So the trust of analysts is improving.
AVIR was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-13 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2023-08-10 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2023-03-16 | JP Morgan | Maintains | Neutral |
| 2023-01-27 | SVB Leerink | Maintains | Market Perform |
| 2023-01-24 | Morgan Stanley | Maintains | Underweight |
| 2022-08-15 | Morgan Stanley | Maintains | Underweight |
| 2022-03-02 | JP Morgan | Maintains | Neutral |
| 2022-03-01 | SVB Leerink | Maintains | Market Perform |
| 2022-02-16 | SVB Leerink | Maintains | Market Perform |
| 2022-01-06 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-11-18 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-10-20 | SVB Leerink | Maintains | Outperform |
| 2021-10-20 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-10-05 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-09-09 | SVB Leerink | Initiate | Outperform |
| 2021-08-18 | Morgan Stanley | Maintains | Overweight |
| 2021-06-03 | Morgan Stanley | Maintains | Overweight |
| 2021-04-06 | Morgan Stanley | Maintains | Overweight |